Need professional-grade analysis? Visit stockanalysis.com
$488.47M
28.25
243
2.31%
Revenio Group Corporation (REG1V) trades on Nasdaq Helsinki in EUR. The company is classified in the Healthcare sector under the Medical Devices industry. The stock currently trades at EUR16.96, down 0.24% from the previous close.
Over the past year, REG1V has traded between a low of EUR16.96 and a high of EUR29.65. The stock has lost 25.6% over this period. It is currently 42.8% below its 52-week high.
Revenio Group Corporation has a market capitalization of $488.47M, with a price-to-earnings ratio of 28.25 and a dividend yield of 2.31%.
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Probes that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used for measuring IOP on animal patients by general veterinary practitioners, veterinary ophthalmologists and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
Side-by-side comparison against top Healthcare peers.